摘要
目的评估绝经期乳腺癌妇女服用他莫昔芬(tamoxifen,TAM)后Ki-67、Fas及Fasl在子宫内膜中的表达。方法2001-01-2004-08采用免疫组化法测定北京天坛医院妇科46例TAM组及18例对照萎缩内膜组子宫内膜中Ki-67、Fas、Fasl的表达。结果TAM组与对照组比较,Ki-67及Fasl呈明显高表达(分别为15·41±4·83、9·05±5·52,P=0·009;0·46±0·14、0·39±0·10,P=0·037);Fas未呈高表达(0·28±0·13:0·31±0·11,P=0·387)。结论TAM能够引起绝经期子宫内膜增生,并不促进细胞凋亡,这些细胞增殖与凋亡因子及其发挥作用的通路可能在绝经后TAM服用者子宫内膜病变的发病机制中起作用。
Objective The aim of the present study was to investigate the effects of tamoxifen （TAM） on expression of Ki-67 antigen, Fas and Fas ligand （Fasl） in postmenopausal endometrium. Methods Forty-six postmenopausal breast cancer patients receiving 20mg/day TAM for at least six months were examined by hysteroscopy and endometrial biopsy, and eighteen age-matched, non-hormonally treated patients with atrophic endometrium of vaginal hysterectomy because of uterine prolapse served as comparison groups. Immunohistochemical studies for the expression of Ki-67 antigen, Fas and Fasl in endometrium were performed. Results There were significantly increased levels of expression of Ki-67 antigen （ 15.41±4. 83 vs 9.05 ± 5.52, P = 0. 009） in glandular epithelium in tamoxifen-associated endometrium compared with atrophic endometrium. Also, Fasl was expressed more frequently in glandular epithelium in the tamoxifen samples（0.46 ±0. 14 vs 0. 39 ±0. 10, P =0. 037）. The expression of Fas in glandular epithelium did not differ between tamoxifen-associated endometrium and atrophic endometrium （0. 28 ± 0. 13 vs 0. 31 ± 0. 11, P = 0. 387 ）. Conclusion In postmenopa- usal women tamoxifen exerts a proliferative effect on the endometrium, as measured by Ki-67 antigen, but is not compensated for by increased apeptosis, as measured by Fas. These cell proliferative and apeptosis factors, and the pathways in which they function may contribute to the pathogenesis of tamoxifen-assoeiated hyperplastic and carcinogenic properties for the endometrium.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2006年第12期903-905,共3页
Chinese Journal of Practical Gynecology and Obstetrics
基金
首都医科大学基础与临床科研合作基金(04JL20)资助项目
关键词
他莫昔芬
子宫内膜
绝经期
增殖
凋亡
Tamoxifen
Endometrium
Menopause
Proliferation
Apoptosis
